Literature DB >> 10639262

Adjunctive Pharmacologic Treatment: Focus on the Development of Low Molecular Weight Heparins.

.   

Abstract

Entities:  

Year:  1997        PMID： 10639262     DOI： 10.1023/a:1008870228789

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  79 in total

1.  Preliminary experience with intravascular ultrasound guided Palmaz-Schatz coronary stenting: the acute and short-term results on a consecutive series of patients.

Authors:  P Hall; A Colombo; Y Almagor; L Maiello; S Nakamura; G Martini; J M Tobis
Journal:  J Interv Cardiol       Date:  1994-04       Impact factor: 2.279

Review 2.  Surface-dependent reactions of the vitamin K-dependent enzyme complexes.

Authors:  K G Mann; M E Nesheim; W R Church; P Haley; S Krishnaswamy
Journal:  Blood       Date:  1990-07-01       Impact factor: 22.113

3.  Safety of high doses of low molecular weight heparin (Fragmin) in acute myocardial infarction. A dose-finding study.

Authors:  A Nesvold; F Kontny; U Abildgaard; J Dale
Journal:  Thromb Res       Date:  1991-12-01       Impact factor: 3.944

4.  Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study.

Authors:  V V Kakkar; W J Murray
Journal:  Br J Surg       Date:  1985-10       Impact factor: 6.939

5.  Angiographic and clinical outcome of intracoronary stenting: immediate and long-term results from a large single-center experience.

Authors:  J P Carrozza; R E Kuntz; M J Levine; R M Pomerantz; R F Fishman; M Mansour; C M Gibson; C C Senerchia; D J Diver; R D Safian
Journal:  J Am Coll Cardiol       Date:  1992-08       Impact factor: 24.094

6.  A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery.

Authors:  A G Turpie; M N Levine; J Hirsh; C J Carter; R M Jay; P J Powers; M Andrew; R D Hull; M Gent
Journal:  N Engl J Med       Date:  1986-10-09       Impact factor: 91.245

7.  Low molecular weight heparin (CY-216) versus unfractionated heparin in chronic hemodialysis.

Authors:  E Grau; F Sigüenza; F Maduell; M Linares; M A Olaso; R Martinez; A Caridad
Journal:  Nephron       Date:  1992       Impact factor: 2.847

8.  Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin.

Authors:  M Koller; U Schoch; P Buchmann; F Largiadèr; A von Felten; P G Frick
Journal:  Thromb Haemost       Date:  1986-12-15       Impact factor: 5.249

9.  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1993-11-25       Impact factor: 91.245

10.  Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis.

Authors:  J Harenberg; K Huck; H Bratsch; G Stehle; C E Dempfle; K Mall; M Blauth; K H Usadel; D L Heene
Journal:  Haemostasis       Date:  1990
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.